Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide.
Dikshyanta RanaClaudia GeueKelly BaillieJiafeng PanTanja MuellerJennifer LaskeyMarion BennieJulie ClarkeRobert J JonesAilsa BrownOlivia WuPublished in: PharmacoEconomics - open (2021)
The total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data.